Atomo Appoints Interim Chair
Released
Released
Announcement PDF
ASX Announcement
23 May 2025
Atomo Appoints Interim Chair
SYDNEY Australia, 23 May 2025 – Atomo Diagnostics Limited (ASX: AT1) (Atomo or the Company)
advises that the Board has appointed Mr John Kelly, the Company’s current Chief Executive Officer
and Managing Director, as Interim Chair of the Board.
This interim appointment follows recent changes to the composition of the Board and is considered
appropriate at this time for Mr Kelly to assume the role of Chair on an interim basis to ensure continuity
and stability in the leadership of the Company during this period.
The Board is committed to strong corporate governance and intends to appoint a permanent
independent Chair in due course.
The Company will keep shareholders informed as further updates become available. There will be no
changes to Mr Kelly’s remuneration.
~ ENDS ~
For more information, please contact:
John Kelly
Managing Director & CEO & Interim Chair
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279
This announcement was authorised by the Board.
About Atomo
Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid
diagnostic test (RDT) devices to the global diagnostic market.
Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability
across rapid point-of-care (POC) and at-home testing applications. The Company has successfully
commercialised a number of products across international markets and has supply agreements in place
for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial
differentiation, as well as the early detection of pregnancy.
See more at www.atomodiagnostics.com
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
Share your feedback
Discover